Possible role of Spironolactone in a sample of Iraqi patients with acute central serous chorioretinopathy

Spironolactone in acute csr

Authors

  • Marwa Majeed Hameed Opthalmology department, Ghazi Al- Hariri hospital, Baghdad, Iraq
  • Ahmed Majeed Rasheed College of Medicine, Al-Nahrain University, Baghdad, Iraq
  • Furkaan Majeed Hameed College of Medicine, Al-Qadisiyah University, Diwanyah, Iraq

DOI:

https://doi.org/10.47723/kcmj.v18i1.668

Keywords:

Central serous chorioretinopathy, Spironolactone

Abstract

Background: Central serous chorioretinopathy (CSCR) is an idiopathic condition aggravated by exogenous or endogenous glucocorticoids. Vascular deregulation in the choroid is a new hypothesis regarding central serous chorioretinopathy occurrence. The inhibition of choroidal mineralocorticoid receptors has a great role in shortening the duration of CSCR by inhibiting choroidal vasodilatation and leak.

Objective:  To assess the effect of oral spironolactone on subretinal fluid, central macular thickness and visual acuity in patients with acute CSCR compared to observation.

Subjects and Methods:  a hospital based, randomized clinical trial carried out at outpatient clinic in Ibn-Alhaitham Teaching Eye Hospital/ Baghdad, enrolling 60 patients with acute unilateral CSCR, allocated randomly (every other patient) to either receiving spironolactone 25 mg orally, twice daily for 2 months (30 patients) or observation only (30 patients). The follow-up included visual acuity measurement, central macular thickness and subretinal fluid height examinations by ocular coherence tomography (OCT) at one- and two-months post enrollment for all patients.

Results: Complete absorption of subretinal fluid was observed in 21(70%) of the eyes in the treatment group and in 6(20%) in the control group at two-months. Visual acuity and mean macular thickness improved significantly in both groups at the one- and two- months, mean changes was larger in treatment group compared to control group at the two-month-follow up endpoint.

Conclusion: Oral spironolactone imparted greater improvement in central macular thickness and faster resolution of sub retinal fluid in patients with acute central serous chorioretinopathy versus observation.

Downloads

Published

2022-05-05

How to Cite

Hameed, M. M., Rasheed, A. . M. ., & Hameed, F. M. . (2022). Possible role of Spironolactone in a sample of Iraqi patients with acute central serous chorioretinopathy: Spironolactone in acute csr. AL-Kindy College Medical Journal, 18(1), 60–64. https://doi.org/10.47723/kcmj.v18i1.668